Tag Archive: European Society of Cardiology (ESC)

Sep 19

Beta-blockers are of zero benefit in patients with heart failure and reduced ejection fraction if they also have atrial fibrillation

Beta-blockers are of zero benefit in patients with heart failure and reduced ejection fraction if they also have atrial fibrillation. Dr Dipak Kotecha (University of Birmingham, UK) presented the analysis Tuesday during the final clinical-trial-update session of the European Society of Cardiology (ESC) 2014 Congress published simultaneously in The Lancet.

Sep 13

A meta-analysis of 11 trials in patients 65 years or older reported that antihypertensive medications are significantly

A meta-analysis of 11 trials in patients 65 years or older reported that antihypertensive medications are significantly more effective than placebo in lowering blood pressure and are linked with significantly lower relative risks of death from all causes and from cardiac causes. However, only one study reported that blood-pressure–lowering medication was tied to a 21% …

Continue reading »

Sep 12

The study was presented at the European Society of Cardiology (ESC) 2014 Congress.

Compared with normal weight children, obese girls were 5.9 times more likely to have hypertension and obese boys were 4.3 times more likely to have hypertension, according to a new study. Even being overweight increased the risk of prehypertension and hypertension. The study was presented at the European Society of Cardiology (ESC) 2014 Congress.

Sep 11

The data were presented at the European Society of Cardiology (ESC) 2014 Congress.

The International Fixed Dose Combination Drug for Secondary Cardiovascular Prevention (FOCUS) trial of patients who had survived an MI showed that taking a fixed–dose combination aspirin/simvastatin/ramipril polypill increases the odds of perfect pill compliance; however, only about half of the patients were consistently taking the polypill at the nine–month study end. The data were presented …

Continue reading »

Sep 10

Starting patients on an eight–week course of amiodarone immediately after ablation for atrial fibrillation (AF)

Starting patients on an eight–week course of amiodarone immediately after ablation for atrial fibrillation (AF) may not reduce the risk of AF recurrence over the next six months, suggests a small study, presented recently at the European Society of Cardiology (ESC) 2014 Congress. However, a lower risk of atrial arrhythmias within three months of ablation …

Continue reading »

Sep 08

The report was presented at the European Society of Cardiology (ESC) 2014 Congress.

A new analysis from the FAST–MI registry revealed that continuing beta-blocker therapy over long–term in post–AMI patients with preserved ejection fraction may not be justified. The report was presented at the European Society of Cardiology (ESC) 2014 Congress.

Sep 07

The data has been presented at the European Society of Cardiology (ESC) 2014 Congress.

Two–year results from the FAME–2 study have shown that PCI is superior to medical therapy for the reduction of hard clinical end points in patients with stable coronary artery disease. Researchers stressed that PCI is superior to medical therapy as along as fractional flow reserve (FFR) is used to guide treatment decisions. The data has …

Continue reading »

Sep 06

The CONFIRM HF study, presented at the European Society of Cardiology (ESC) 2014 Congress

The CONFIRM HF study, presented at the European Society of Cardiology (ESC) 2014 Congress, has revealed that iron supplementation in patients with chronic heart failure and iron deficiency improves functional capacity, symptoms, and quality of life.

Sep 05

A study presented at the European Society of Cardiology (ESC)

A study presented at the European Society of Cardiology (ESC) 2014 Congress has shown that beta–blockers are of no benefit in patients with heart failure and reduced ejection fraction if they also have atrial fibrillation. The study was published simultaneously in the Lancet.

Aug 31

Authors of an extremely critical analysis published in the BMJ have asked the European Society of Cardiology (ESC)

Authors of an extremely critical analysis published in the BMJ have asked the European Society of Cardiology (ESC) to revise its recent guidance pertaining to the use of beta–blockers in patients undergoing noncardiac surgery, to mend its guideline process to be more transparent, and to act much more swiftly to revise recommendations when patient lives …

Continue reading »

Older posts «